Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATA3219

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Atara Biotherapeutics

Phase 1 Most advanced trial (none active)

ATRA Developer

1 Registered trials

What is ATA3219?

ATA3219 is an allogeneic, Epstein-Barr virus-sensitized T-lymphocyte preparation engineered to express a chimeric antigen receptor directed at CD19. The CAR uses a modified CD3zeta signaling domain that retains signaling in one of three ITAM regions. It is being studied in relapsed or refractory B-cell non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Targets: CD19 (antigen)
Mechanism: Kills target cells, directed at CD19
Therapy area: Oncology
Developer: Atara Biotherapeutics (ATRA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06256484	Phase 1	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	Terminated	ATRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

More from Atara Biotherapeutics

Tabelecleucel Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ATRA page.

Follow ATRA, the company behind ATA3219

See ATRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATRA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z